A detailed history of First Republic Investment Management, Inc. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, First Republic Investment Management, Inc. holds 31,294 shares of IOVA stock, worth $254,733. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31,294
Previous 19,751 58.44%
Holding current value
$254,733
Previous $139,000 2.16%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

BUY
$4.44 - $8.79 $51,250 - $101,462
11,543 Added 58.44%
31,294 $142,000
Q2 2023

Jul 28, 2023

SELL
$5.36 - $9.06 $6,608 - $11,170
-1,233 Reduced 5.88%
19,751 $139,000
Q1 2023

May 11, 2023

SELL
$5.53 - $8.22 $12,210 - $18,149
-2,208 Reduced 9.52%
20,984 $128,000
Q4 2022

Feb 13, 2023

BUY
$5.62 - $10.0 $24,784 - $44,100
4,410 Added 23.48%
23,192 $148,000
Q3 2022

Nov 03, 2022

BUY
$9.53 - $13.11 $4,364 - $6,004
458 Added 2.5%
18,782 $180,000
Q2 2022

Aug 16, 2022

BUY
$6.38 - $18.33 $30,981 - $89,010
4,856 Added 36.06%
18,324 $202,000
Q1 2022

May 16, 2022

BUY
$12.38 - $19.1 $4,568 - $7,047
369 Added 2.82%
13,468 $224,000
Q4 2021

Feb 09, 2022

SELL
$16.55 - $27.63 $57,941 - $96,732
-3,501 Reduced 21.09%
13,099 $250,000
Q3 2021

Nov 12, 2021

SELL
$20.35 - $26.63 $1,607 - $2,103
-79 Reduced 0.47%
16,600 $409,000
Q2 2021

Aug 16, 2021

BUY
$16.33 - $33.07 $67,132 - $135,950
4,111 Added 32.71%
16,679 $434,000
Q1 2021

May 14, 2021

BUY
$28.67 - $52.59 $3,899 - $7,152
136 Added 1.09%
12,568 $398,000
Q4 2020

Feb 16, 2021

SELL
$28.04 - $50.26 $101,000 - $181,036
-3,602 Reduced 22.46%
12,432 $577,000
Q3 2020

Nov 12, 2020

BUY
$27.75 - $36.3 $3,829 - $5,009
138 Added 0.87%
16,034 $528,000
Q2 2020

Aug 13, 2020

BUY
$27.21 - $41.0 $157,382 - $237,144
5,784 Added 57.2%
15,896 $436,000
Q1 2020

May 13, 2020

BUY
$19.54 - $38.85 $197,588 - $392,851
10,112 New
10,112 $303,000

Others Institutions Holding IOVA

About IOVANCE BIOTHERAPEUTICS, INC.


  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.28B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track First Republic Investment Management, Inc. Portfolio

Follow First Republic Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Republic Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Republic Investment Management, Inc. with notifications on news.